• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    7/31/24 5:01:23 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ME alert in real time by email
    SC 13D/A 1 sc13d-a2.htm SCHEDULE 13D, AMENDMENT NO. 2
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    RULE 13d-2(a)  
     

    23ANDME HOLDING CO.
    (Name of Issuer)


    Class A Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
    90138Q 108
    (CUSIP Number)
    ABEEC 2.0, LLC
    171 Main Street, Suite 259
    Los Altos, California 94022
    THE ANNE WOJCICKI REVOCABLE TRUST U/A/D 9/2/09, AS AMENDED AND RESTATED
    Trustee Anne Wojcicki
    171 Main Street, Suite 259
    Los Altos, California 94022
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    Copies To:
    Graham Robinson
    Chadé Severin
    Skadden, Arps, Slate, Meagher & Flom LLP
    500 Boylston Street, 23rd Floor
    Boston, Massachusetts 02116
    July 29, 2024
    (Date of Event Which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box  ☐.
     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.
     

    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes.)
     




    1.
    Names of Reporting Persons
     
    ABeeC 2.0, LLC
    2.
    Check the Appropriate Box if a Member of a Group
    (a)  ☐        (b)  ☐
     
    3.
    SEC Use Only
     
    4.
    Source of Funds (See Instructions)
     
    N/A
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
     
    ☐
    6.
    Citizenship or Place of Organization
     
    Delaware
    Number of
    Shares
     Beneficially 
    Owned by
    Each
    Reporting
    Person
    With 
    7.
    Sole Voting Power
     
    0
    8.
    Shared Voting Power
     
    98,633,827 (1)(2)(3) (see Item 5)
    9.
    Sole Dispositive Power
     
    0
    10.
    Shared Dispositive Power
     
    98,633,827 (1)(3) (see Item 5)
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    98,633,827 (3) (see Item 5)
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares
     
    ☐
    13.
    Percent of Class Represented by Amount in Row (11)
     
    22.5% (4)
    14.
    Type of Reporting Person
     
    OO

    (1)
    The ANNE WOJCICKI REVOCABLE TRUST U/A/D 9/2/09, AS AMENDED AND RESTATED (the “Trust”) is the sole member of ABeeC 2.0, LLC (the “LLC”) and Anne Wojcicki is the sole trustee of the Trust. Accordingly, the LLC, the Trust, and Ms. Wojcicki have shared power to vote and dispose, or direct the disposition, of 98,633,827 shares of the Class B common stock, par value $0.0001 per share (the “Class B Common Stock”) of 23andMe Holding Co. (the “Issuer”) held by the LLC.
    (2)
    The LLC is manager-managed and the manager from time to time may exercise voting power with respect to the shares of Class B Common Stock held by the LLC.
    (3)
    Represents shares of the Issuer’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) that may be obtained upon the conversion of shares of Class B Common Stock held by the reporting persons. Class B Common Stock, which is not registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is convertible into shares of Class A Common Stock on a share-for-share basis.
    (4)
    Based upon (a) 339,502,600 shares of Class A Common Stock outstanding as of July 1, 2024, as disclosed in the Issuer’s Proxy Statement filed on Schedule 14A with the Securities and Exchange Commission (“SEC”) on July 16, 2024, and (b) 98,633,827 shares of Class A Common Stock issuable upon conversion of the Class B Common Stock held by the LLC.




    1.
    Names of Reporting Persons
     
     THE ANNE WOJCICKI REVOCABLE TRUST U/A/D 9/2/09, AS AMENDED AND RESTATED
    2.
    Check the Appropriate Box if a Member of a Group
    (a)  ☐        (b)  ☐
     
    3.
    SEC Use Only
     
    4.
    Source of Funds (See Instructions)
     
    N/A
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
     
    ☐
    6.
    Citizenship or Place of Organization
     
     California
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With
    7.
    Sole Voting Power
     
    0
    8.
    Shared Voting Power
     
    98,633,827 (1)(2)(3) (see Item 5)
    9.
    Sole Dispositive Power
     
    0
    10.
    Shared Dispositive Power
     
    98,633,827 (1)(3) (see Item 5)
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    98,633,827 (3) (see Item 5)
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares
     
    ☐
    13.
    Percent of Class Represented by Amount in Row (11)
     
    22.5% (4)
    14.
    Type of Reporting Person
     
    OO
     
    (1)
    Represents shares of Class B Common Stock held by LLC. The Trust is the sole member of the LLC and Ms. Wojcicki is the sole trustee of the Trust. Accordingly, the LLC, the Trust, and Ms. Wojcicki have shared power to vote and dispose, or direct the disposition, of 98,633,827 shares of the Class B Common Stock held by the LLC.
    (2)
    The LLC is manager-managed and the manager from time to time may exercise voting power with respect to the shares of Class B Common Stock held by the LLC.
    (3)
    Represents shares of the Issuer’s Class A Common Stock that may be obtained upon the conversion of shares of Class B Common Stock held by the reporting persons. The Class B Common Stock, which is not registered under the Exchange Act, is convertible into shares of Class A Common Stock on a share-for-share basis.
    (4)
    Based upon (a) 339,502,600 shares of Class A Common Stock outstanding as of July 1, 2024, as disclosed in the Issuer’s Proxy Statement filed on Schedule 14A with the SEC on July 16, 2024, and (b) 98,633,827 shares of Class A Common Stock issuable upon conversion of the Class B Common Stock held by the LLC.




    1.
    Names of Reporting Persons
     
     Anne Wojcicki
    2.
    Check the Appropriate Box if a Member of a Group
    (a)  ☐        (b)  ☐
     
    3.
    SEC Use Only
     
    4.
    Source of Funds (See Instructions)
     
     PF
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
     
    ☐
    6.
    Citizenship or Place of Organization
     
     United States
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With
     
    7.
    Sole Voting Power
     
    8,801,212 (1)
    8.
    Shared Voting Power
     
    101,133,827 (2)(3)(4)(5)(6) (see Item 5)
    9.
    Sole Dispositive Power
     
    8,801,212 (1)
    10.
    Shared Dispositive Power
     
    101,133,827 (2)(3)(5)(6) (see Item 5)
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    109,935,039 (1)(2)(6) (see Item 5)
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares
     
    ☐
    13.
    Percent of Class Represented by Amount in Row (11)
     
    24.7% (7)
    14.
    Type of Reporting Person
     
    IN

    (1)
    Includes (a) 1,016,095 shares of Class A Common Stock held directly by Ms. Wojcicki, (b) 7,706,955 stock options held by Ms. Wojcicki that have vested or will vest within sixty days of the date hereof, and (c) 78,162 restricted stock units held directly by Ms. Wojcicki that will vest within sixty days of the date hereof.
    (2)
    Includes indirect beneficial ownership of (a) 98,633,827 shares of Class B Common Stock held by the LLC and (b) 2,500,000 shares of Class A Common Stock held by The Anne Wojcicki Foundation (“AWF”), for which Ms. Wojcicki disclaims beneficial ownership except to the extent of her pecuniary interest therein.
    (3)
    The Trust is the sole member of the LLC and Ms. Wojcicki is the sole trustee of the Trust. Accordingly, the LLC, the Trust, and Ms. Wojcicki have shared power to vote and dispose, or direct the disposition, of 98,633,827 shares of the Class B Common Stock held by the LLC.
    (4)
    The LLC is manager-managed and the manager from time to time may exercise voting power with respect to the shares of Class B Common Stock held by the LLC.
    (5)
    Ms. Wojcicki, as the President and Chairman of the Board of AWF, has shared power to vote and dispose, or direct the disposition, of 2,500,000 shares of Class A Common Stock held by AWF.
    (6)
    Includes 98,633,827 shares of the Class A Common Stock that may be obtained upon the conversion of shares of Class B Common Stock held by the reporting persons. Class B Common Stock, which is not registered under the Exchange Act, is convertible into shares of Class A Common Stock on a share-for-share basis.
    (7)
    Based upon (a) 339,502,600 shares of Class A Common Stock outstanding as of July 1, 2024, as disclosed in the Issuer’s Proxy Statement filed on Schedule 14A with the Securities and Exchange Commission (“SEC”) on July 16, 2024, (b) 98,633,827 shares of Class A Common Stock issuable upon conversion of the Class B Common Stock held by the LLC, (c) 7,706,955 shares of Class A Common Stock issuable upon the exercise of options held by Ms. Wojcicki that have vested or will vest within sixty days of the date hereof, and (d) 78,162 restricted stock units held by Ms. Wojcicki that will vest within sixty days of the date hereof.





    Explanatory Note

    This Amendment No. 2 (“Amendment No. 2”) to Schedule 13D relates to the Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) of 23andMe Holding Co., a Delaware corporation (the “Issuer”), and amends and supplements the initial statement on Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission (“SEC”) on June 25, 2021, as amended by Amendment No. 1 filed on April 17, 2024 (collectively, the “Initial Schedule 13D”, and as amended and supplemented by this Amendment No. 2, the “Schedule 13D”).  Capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings ascribed to them in the Schedule 13D.

    ITEM 4.
    Purpose of the Transaction.

    Item 4 of the Schedule 13D is hereby amended and restated as follows:

    The information set forth in Item 3 of this Schedule 13D is incorporated into this Item 4 by reference.

    Ms. Wojcicki serves as a member of the Issuer’s Board of Directors (the “Board”)  and as its Chief Executive Officer. In such capacity, Ms. Wojcicki may have influence over the corporate activities of the Issuer, including activities that may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

    The Reporting Persons hold the securities of the Issuer for general investment purposes. Other than as described below, the Reporting Persons do not currently have any plans or proposals that relate to, or would result in, any of the items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.  The Reporting Persons may, at any time and from time to time, acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. The Reporting Persons may engage in discussions with the Issuer’s senior management, the Board, stockholders and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore material changes to the business plan or capitalization of the Issuer. Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons’ review of numerous factors, including, but not limited to, an ongoing evaluation of the Issuer’s business, financial condition, operations and prospects; price levels of the Issuer’s securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments. The Reporting Persons reserve the right, based on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to acquire additional shares of Class A Common Stock, Class B Common Stock, or other securities of the Issuer, dispose of some or all of the shares of Class A Common Stock, Class B Common Stock, or other securities of the Issuer that they may own from time to time, in each case in open market or private transactions, block sales or otherwise or pursuant to ordinary stock exchange transactions effected through one or more broker-dealers whether individually or utilizing specific pricing or other instructions (including by means of Rule 10b5-1 programs).

    On April 13, 2024, Ms. Wojcicki notified members of the special committee (the “Special Committee”) of the Board that she was considering making a proposal to acquire the Issuer in a potential go-private transaction. Ms. Wojcicki indicated that she was working with advisors and intended to begin speaking to potential partners and financing sources. Ms. Wojcicki stated that any proposal by her would be conditioned irrevocably upon the approval of the Special Committee and a majority of the unaffiliated stockholders of the Issuer. Ms. Wojcicki also indicated that she wished to maintain control of the Issuer and, therefore, would not be willing to support any alternative transaction.






    On July 29, 2024, Ms. Wojcicki delivered a non-binding proposal to the Special Committee, pursuant to which she would be willing to enter into a transaction to acquire all of the Issuer’s outstanding shares of common stock not owned by her or her affiliates or any other stockholders she invites to “roll-over” their current equity shares for cash consideration of $0.40 per share of Class A Common Stock or Class B Common Stock (the “Proposal”). The Proposal indicated that Ms. Wojcicki continued to have discussions with potential equity financing sources and the potential transaction would be fully financed by committed equity financing. The Proposal also indicated that the potential transaction, and any other corporate acts related to the potential transaction, are conditioned upon the approval of (1) the Special Committee and (2) the majority of shares that are not held by Ms. Wojcicki, her affiliates or stockholders invited to “roll-over” their current equity shares by her. In the Proposal, Ms. Wojcicki again stated that she would not expect to support any alternative transaction.

    The foregoing is a summary of the Proposal and is qualified in its entirety by reference to the full text of the Proposal, a copy of which is attached hereto as Exhibit 1 and incorporated by reference herein.

    The Proposal may result in one or more of the transactions, events or actions specified in subparagraphs (a) through (j) of Item 4 of Schedule 13D, including without limitation, an acquisition of additional securities of the Issuer, an extraordinary corporate transaction (such as a merger) involving the Issuer, delisting of the Common Stock of the Issuer and other material changes to the Issuer’s business or corporate structure.

    There can be no assurance that the foregoing, or anything related to the Proposal, will result in any definitive agreement, transaction or any other strategic alternative and or whether or when any of the foregoing may happen. Notwithstanding anything contained herein, the Reporting Persons reserve the right to modify or withdraw the Proposal at any time. The Reporting Persons reserve the right to formulate other plans or make other proposals which could result in one or more of the transactions, events or actions specified in subparagraphs (a) through (j) of Item 4 of Schedule 13D, and to modify or withdraw any such plan or proposal at any time.

    The Reporting Persons do not intend to update additional disclosures regarding the Proposal until a definitive agreement has been reached, or unless disclosure is otherwise required under applicable U.S. securities laws. The Reporting Persons intend to engage in discussions with the Special Committee regarding the terms of the Proposal. The Reporting Persons may change the terms of the Proposal, determine to accelerate or terminate discussions with the Special Committee with respect to the Proposal, withdraw the Proposal, take any action to facilitate or increase the likelihood of consummation of the Proposal, or change their intentions with respect to any such matters, in each case at any time and without prior notice. The Reporting Persons and their affiliates will, directly or indirectly, continue to take and take such additional steps as they may deem appropriate to further the Proposal or otherwise to support their investment in the Issuer, including, without limitation: (i) engaging in discussions with advisors and other relevant parties and (ii) entering into confidentiality arrangements and other agreements, arrangements and understandings in connection with the Proposal.

    Neither the Proposal nor this Amendment No. 2 is meant to be, nor should be construed as, an offer to buy or the solicitation of an offer to sell any of the Issuer’s securities.
     
    ITEM 5.
    Interest in Securities of Issuer.

    Items 5(a)-(c) of the Schedule 13D are hereby amended and restated as follows:

    (a) The LLC is the record and beneficial owner of 98,633,827 shares of the Issuer’s Class B Common Stock, which may be converted into the same number of shares of Class A Common Stock, representing beneficial ownership of 22.5% of outstanding shares of Class A Common Stock and 59.2% of the outstanding shares of Class B Common Stock.

    The Trust is the sole member of the LLC and therefore may be deemed to beneficially own the 98,633,827 shares of Class B Common Stock held by the LLC, which may be converted into the same number of shares of Class A Common Stock, representing beneficial ownership of 22.5% of the outstanding shares of Class A Common Stock and 59.2% of the outstanding shares of Class B Common Stock.




    Ms. Wojcicki is the sole trustee of the Trust and the President and Chairman of the Board of AWF. Accordingly, Ms. Wojcicki may be deemed the beneficial owner of an aggregate of 109,935,039 shares of Class A Common Stock, consisting of: (a) 1,016,095 shares of Class A Common Stock held directly by Mr. Wojcicki, (b) 7,706,955 stock options held directly by Ms. Wojcicki that have vested or will vest within sixty days of the date hereof, (c) 78,162 restricted stock units held directly by Ms. Wojcicki that will vest within sixty days of the date hereof, (d) 98,633,827 shares of Class B Common Stock held by the LLC, which may be converted into the number of shares of Class A Common Stock, and (e) 2,500,000 shares of Class A Common Stock held by AWF, representing beneficial ownership of 24.7% of the outstanding shares of Class A Common Stock and 59.2% of the outstanding shares of Class B Common Stock; provided, however, the foregoing amounts include Ms. Wojcicki’s indirect ownership of (i) 98,633,827 shares of Class B Common Stock held by the LLC and (ii) 2,500,000 shares of Class A Common Stock held by AWF, for which Ms. Wojcicki disclaims beneficial ownership except to the extent of her pecuniary interest therein.

    The calculation of the Class A Common Stock beneficial ownership percentages in this Item 5 are based upon  (a) 339,502,600 shares of Class A Common Stock outstanding as of July 1, 2024, as disclosed in the Issuer’s Proxy Statement filed on Schedule 14A with the SEC on July 16, 2024 (the “Proxy Statement”), and (b) any shares of Class A Common Stock issuable upon the conversion, exercise and/or vesting of Class B Common Stock, stock options, restricted stock units or other convertible securities held by each Reporting Person (including any such securities that have vested or will vest within sixty days of the date hereof), as applicable. The calculation of the Class B Common Stock beneficial ownership percentages are based upon 166,507,453 shares of Class B Common Stock outstanding as of July 1, 2024, as disclosed in the Proxy Statement.

    By virtue of the relationships described herein, the Reporting Persons may be deemed to constitute a “group” within the meaning of Rule 13d-5 under the Exchange Act. As a member of a group, each Reporting Person may be deemed to share voting and dispositive power with respect to, and therefore beneficially own, the securities of the Issuer beneficially owned by members of the group as a whole. The filing of this Statement on Schedule 13D shall not be construed as an admission that the Reporting Persons beneficially own those securities held by another member of such group. In addition, each Reporting Person expressly disclaims beneficial ownership of any securities reported herein except to the extent such Reporting Person actually exercises voting or dispositive power with respect to such securities.

    (b) The LLC, the Trust (as the sole member of LLC), and Ms. Wojcicki (as the sole trustee of the Trust) have shared power to vote and dispose, or direct the disposition, of 98,633,827 shares of the Class B Common Stock held by the LLC. Additionally, the LLC is manager-managed and the manager from time to time may exercise voting power with respect to the shares of Class B Common Stock held by the LLC.

    Ms. Wojcicki, as the President and Chairman of the Board of AWF, has shared power to vote and dispose, or direct the disposition, of 2,500,000 shares of Class A Common Stock held by AWF. AWF is a 501(c)(3) non-profit organization; its address is 171 Main Street, Suite 259, Los Altos, California 94022. During the last five years, AWF has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). During the last five years, AWF has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and has not been and is not, as a result of such proceeding, subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

    Ms. Wojcicki has sole power to vote and dispose, or direct the disposition, of the securities reported herein as directly held by her.

    (c) There have been no reportable transactions with respect to the Common Stock of the Issuer within the last 60 days by the Reporting Persons, except as described in this Schedule 13D.

    ITEM 6.
    Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 of the Schedule 13D is hereby amended and supplemented by the following:




    The information set forth in Item 4 of this Schedule 13D is incorporated into this Item 6 by reference.

    ITEM 7.
    Materials to be Filed as Exhibits.

    Exhibit 1 — Nonbinding Proposal Letter delivered to the Special Committee of the Board of Directors of the Issuer, dated as of July 29, 2024.




    SIGNATURES
    After reasonable inquiry and to the best of its knowledge and belief, the undersigned each certifies that the information with respect to it set forth in this Schedule 13D is true, complete, and correct.
    Dated: July 29, 2024


     
    ABeeC 2.0, LLC
     
           
     
    By:  
    /s/ Ryan Batenchuk
     
       
    Name: Ryan Batenchuk
     
       
    Title: Manager
     
           
     
    THE ANNE WOJCICKI REVOCABLE TRUST U/A/D 9/2/09, AS AMENDED AND RESTATED
     
           
     
    By:  
    /s/ Anne Wojcicki
     
       
    Name: Anne Wojcicki
     
       
    Title: Trustee
     
           
     
    Anne Wojcicki
     
         
     
    /s/ Anne Wojcicki
     




    Get the next $ME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ME

    DatePrice TargetRatingAnalyst
    11/29/2022$7.00Buy
    Berenberg
    9/22/2022$6.00Outperform
    Cowen
    2/11/2022$14.00 → $11.00Outperform
    Credit Suisse
    12/20/2021$13.00 → $9.00Neutral
    Citigroup
    11/15/2021$12.00 → $13.00Buy → Neutral
    Citigroup
    11/11/2021$13.00 → $14.00Outperform
    Credit Suisse
    8/17/2021$13.00Outperform
    Credit Suisse
    7/12/2021$14.00Buy
    Citigroup
    More analyst ratings

    $ME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

    SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for its "first day" motions related to 23andMe's voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the "DIP Facility"

    3/26/25 6:57:42 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

    Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (

    3/23/25 11:08:03 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

    SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee. One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances. Homocysteine is an amino acid that plays a key role in important process

    3/21/25 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Kvarda Matthew

    3 - 23andMe Holding Co. (0001804591) (Issuer)

    3/26/25 4:38:00 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Walper Thomas B.

    3 - 23andMe Holding Co. (0001804591) (Issuer)

    3/26/25 4:35:46 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)

    4 - 23andMe Holding Co. (0001804591) (Issuer)

    2/21/25 5:05:56 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Berenberg initiated coverage on 23andMe with a new price target

    Berenberg initiated coverage of 23andMe with a rating of Buy and set a new price target of $7.00

    11/29/22 7:24:54 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cowen initiated coverage on 23andMe with a new price target

    Cowen initiated coverage of 23andMe with a rating of Outperform and set a new price target of $6.00

    9/22/22 7:20:18 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Credit Suisse reiterated coverage on 23andMe Holding with a new price target

    Credit Suisse reiterated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $11.00 from $14.00 previously

    2/11/22 8:14:04 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    SEC Filings

    View All

    SEC Form 8-K filed by 23andMe Holding Co.

    8-K - 23andMe Holding Co. (0001804591) (Filer)

    3/28/25 4:09:11 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - 23andMe Holding Co. (0001804591) (Filer)

    3/24/25 6:23:28 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by 23andMe Holding Co.

    10-Q - 23andMe Holding Co. (0001804591) (Filer)

    2/6/25 4:27:52 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Financials

    Live finance-specific insights

    View All

    23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

    SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p

    11/12/24 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

    SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23

    11/7/24 5:54:12 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe to Report Q2 FY2025 Financial Results

    SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional

    11/7/24 7:30:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:48:20 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

    11/15/24 4:20:24 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 23andMe Holding Co.

    SC 13G - 23andMe Holding Co. (0001804591) (Subject)

    11/13/24 6:00:29 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ME
    Leadership Updates

    Live Leadership Updates

    View All

    23andMe Appoints Three New Independent Directors to Board

    SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

    10/29/24 7:30:00 AM ET
    $ANSS
    $CDLX
    $LSCC
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Semiconductors

    Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    12/12/23 5:31:00 PM ET
    $EXAS
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

    SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies. Furthermore, 23andMe hopes to help the pharmac

    5/8/23 7:00:00 AM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care